de Menezes Martins Reinaldo, Fernandes Leal Maria da Luz, Homma Akira
a Bio-Manguinhos/Fiocruz ; Rio de Janeiro , Brazil.
Hum Vaccin Immunother. 2015;11(9):2183-7. doi: 10.1080/21645515.2015.1022700.
Yellow fever vaccine was considered one of the safest vaccines, but in recent years it was found that it could rarely cause invasive and disseminated disease in some otherwise healthy individuals, with high lethality. After extensive studies, although some risk factors have been identified, the real cause of causes of this serious adverse event are largely unknown, but findings point to individual host factors. Meningoencephalitis, once considered to happen only in children less than 6 months of age, has also been identified in older children and adults, but with good prognosis. Efforts are being made to develop a safer yellow fever vaccine, and an inactivated vaccine or a vaccine prepared with the vaccine virus envelope produced in plants are being tested. Even with serious and rare adverse events, yellow fever vaccine is the best way to avoid yellow fever, a disease of high lethality and should be used routinely in endemic areas, and on people from non-endemic areas that could be exposed, according to a careful risk-benefit analysis.
黄热病疫苗曾被认为是最安全的疫苗之一,但近年来发现,在一些原本健康的个体中,它极少会引发侵袭性和播散性疾病,且致死率很高。经过广泛研究,虽然已确定了一些风险因素,但这种严重不良事件的真正成因在很大程度上仍不明确,但研究结果指向个体宿主因素。脑膜炎曾被认为仅发生在6个月以下的儿童中,如今在年龄较大的儿童和成人中也有发现,但预后良好。目前正在努力研发更安全的黄热病疫苗,一种灭活疫苗或用植物生产的疫苗病毒包膜制备的疫苗正在进行测试。即便存在严重且罕见的不良事件,黄热病疫苗仍是预防黄热病的最佳方式,黄热病是一种致死率很高的疾病,根据仔细的风险效益分析,在流行地区以及可能暴露的非流行地区人群中应常规使用。